Open To Recruit Trials

Patient: An opportunity to serve the society


  • By participating in a trial, you: Get treated by leading physicians and novel medications that are not available (marketed) globally
  • Get access to potential benefits of a new treatment
  • Receive focus and attention from the best doctors
  • Are alleviated from the financial burden of the treatment
  • Being the focus during the trial, are in charge of your own care that gives you emotional satisfaction
  • Have better access to various support groups and resources that give an additional sense of security
  • This is your opportunity to lay the foundation of research and serve the society towards creating a safe, secured and better future

Principal Investigator: Impact health of people globally


  • You play a central role in developing newer therapies and medical devices that can help patients worldwide
  • By becoming a principal investigator in a trial, you will: Further your knowledge and expertise through the exchange of ideas, studies, and observations made during the trials
  • Play an active role in new drug/treatment development
  • Get an immense amount of personal satisfaction by being proactive in the trial process
  • Get the compensation and play a role in the advancement of medicine
  • Play a role in publication of original research articles
  • Be a leader in your field by bringing newer treatment options that would revolutionise health and welfare of the people globally

Ongoing Trials


A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer


Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer


Phase 2 Study of SAR439859 Versus Physician's Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer


SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients


A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma


Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)


Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden


Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients


Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy


Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC


A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors


An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers


A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)


Evaluation of SAR408701 in Patients With Advanced Solid Tumors


Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A


A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer


An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)


Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers


Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)


Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer


A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)


copyrights © 2020. All rights Reserved.